semaglutide msds Safety Data creratine India Intensifies Regulatory Surveillance Dose:10-Week Starter Program (New Patients Only) - $395

semaglutide msds Safety Data creratine India Intensifies Regulatory Surveillance Dose:10-Week Starter Program (New Patients Only) - $395

India Intensifies Regulatory Surveillance on GLP-1 Weight Loss Drugs to Combat Misuse, ETPharma

Safety Considerations and Reporting Suspected Side Effects The most common adverse effects are gastrointestinal, including nausea, vomiting, and diarrhoea, particularly during dose escalation

creratine

Dose:10-Week Starter Program (New Patients Only) - $395

Patient Selection and Assessment Criteria for patient eligibility, medical history and contraindications According to the package insert: Wegovy® (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management: YES: adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity) NO: Patients with a personal or family history of MTC Patients with MEN 2 Patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in semaglutide WARNING & PRECAUTIONS: Risk of the following: Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Hypoglycemia Acute Kidney Injury Hypersensitivity Reactions Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Heart Rate Increase Suicidal Behavior and Ideation ADDITIONAL Patients should be warned about the following: History of type 1 diabetes or diabetic ketoacidosis, as semaglutide is not indicated for these conditions